# US 2025/0376458 A1 · Compounds and methods for yap/tead modulation and indications therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0376458 A1
- Document ID: US20250376458A1
- Status: Published application
- Kind: A1
- Application number: 19/278,901
- Filed: 2025-07-24
- Published: 2025-12-11
- Earliest claimed: 2023-01-27
- Assignees: Opna Bio SA
- Applicants: Opna Bio SA
- Inventors: Somenath CHOWDHURY
- Web page: https://patentgrep.com/patent/US20250376458A1

## CPC

- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- A61K 31/4375: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A61K 31/4725: containing further heterocyclic rings
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07D 401/14: containing three or more hetero rings
- C07D 413/14: containing three or more hetero rings
- C07D 417/14: containing three or more hetero rings
- C07D 471/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are compounds of Formula (I): or a pharmaceutically acceptable salt, a tautomer, a stereoisomer, or a deuterated analog thereof, wherein ring A, ring B, Q, G, R2, R3, R4, R21, p, q, v, Y1, and Y2 are as described in any of the embodiments described in this disclosure; compositions thereof, and uses thereof.

## Claims

### Claim 1

A compound having Formula (I):
or a pharmaceutically acceptable salt, a tautomer, a stereoisomer, or a deuterated analog thereof, wherein:
Y1 is NR24 and Y2 is N; or
Y1 is N and Y2 is NR24;
R24 is H or C1-C3 alkyl;
ring A is phenyl or a 5- or 6-membered heteroaryl comprising 1-4 heteroatoms selected from N, O and S;
ring B is phenyl, cycloalkyl, or a 5- or 6-membered heteroaryl comprising 1-4 heteroatoms selected from N, O and S,
Q is —O—, —NR20—, —CR22R23—, —CR22R23O—, or —CR22R23NH—; wherein R20 is H or alkyl, R22 is H, halogen, hydroxy, C1-C3 alkyl, or C1-C3 alkoxy, R23 is H, halogen, or C1-C3 alkyl, or R22 and R23 together with the carbon atom to which they are attached, form a carbonyl;
R21 is C1-C6 alkyl optionally substituted with halogen, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, wherein the aryl, heteroaryl, cycloalkyl, heterocycloalkyl are optionally substituted with —O—C1-C6 alkyl; NH2, NH—C1-C6 alkyl, cycloalkyl; or C2-C6 alkenyl;
each G is independently selected from halogen, OH, CN, alkyl optionally substituted with one or more R5, and alkoxy optionally substituted with one or more R5;
each R2 is independently H, halogen, —C(O)O-alkyl, or C1-C3alkyl optionally substituted with 1-3 halogens, provided that not more than one R2 is —C(O)O-alkyl;
R3 is H; halogen; alkenyl optionally substituted with cycloalkyl or heterocycloalkyl; heterocycloalkyl optionally substituted with —C(O)-alkyl; heterocycloalkenyl optionally substituted with C(O)-alkyl; heterocycloalkylalkyl optionally substituted with C(O)-alkyl; or heteroaryl optionally substituted with haloalkyl, cycloalkyl, or cycloalkylalkyl;
R4 is H; alkyl; cycloalkyl optionally substituted with haloalkyl or —C(O)-alkenyl; heterocycloalkyl optionally substituted with —C(O)-alkyl, —C(O)-alkenyl, or —C(O)-cycloalkyl; or heterocycloalkylalkyl optionally substituted with —C(O)-alkyl, —C(O)—CH2—OH, or heteroaryl;
R5 is halogen or OH;
v is 0, 1, 2, 3, or 4;
p is 0, 1, 2, 3, or 4; and
q is 0, 1, or 2.

### Claim 2 (depends on 1)

A compound of claim 1, having a structure of Formula (Ia), (Ib) or (Ic):
or a pharmaceutically acceptable salt, a tautomer, a stereoisomer, or a deuterated analog thereof, wherein:
Y1 is NR24 and Y2 is N; or
Y1 is N and Y2 is NR24;
R24 is H or C1-C3 alkyl;
ring A is phenyl or a 5- or 6-membered heteroaryl comprising 1-4 heteroatoms selected from N, O and S;
ring B is phenyl, cycloalkyl, or a 5- or 6-membered heteroaryl comprising 1-4 heteroatoms selected from N, O and S,
Q is —O—, —NR20—, —CR22R23—, —CR22R23O—, or —CR22R23NH—; wherein R20 is H or alkyl, R22 is H, halogen, hydroxy, C1-C3 alkyl, or C1-C3 alkoxy, R23 is H, halogen, or C1-C3 alkyl, or R22 and R23 together with the carbon atom to which they are attached, form a carbonyl;
R21 is C1-C6 alkyl optionally substituted with halogen, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, wherein the aryl, heteroaryl, cycloalkyl, heterocycloalkyl are optionally substituted with —O—C1-C6 alkyl; NH2, NH—C1-C6 alkyl, cycloalkyl; or C2-C6 alkenyl;
each G is independently selected from halogen, OH, CN, alkyl optionally substituted with one or more R5, and alkoxy optionally substituted with one or more R5;
each R2 is independently H, halogen, —C(O)O-alkyl, or C1-C3alkyl optionally substituted with 1-3 halogens, provided that not more than one R2 is —C(O)O-alkyl;
R3 is H; halogen; alkenyl optionally substituted with cycloalkyl or heterocycloalkyl; heterocycloalkyl optionally substituted with —C(O)-alkyl; heterocycloalkenyl optionally substituted with C(O)-alkyl; heterocycloalkylalkyl optionally substituted with C(O)-alkyl; or heteroaryl optionally substituted with haloalkyl, cycloalkyl, or cycloalkylalkyl;
R4 is H; alkyl; cycloalkyl optionally substituted with haloalkyl or —C(O)-alkenyl; heterocycloalkyl optionally substituted with —C(O)-alkyl, —C(O)-alkenyl, or —C(O)-cycloalkyl; or heterocycloalkylalkyl optionally substituted with —C(O)-alkyl, —C(O)—CH2—OH, or heteroaryl;
R5 is halogen or OH;
v is 0, 1, 2, 3, or 4;
p is 0, 1, 2, 3, or 4; and
q is 0, 1, or 2.

### Claim 3 (depends on 1)

A compound of claim 1,
wherein:
Y1 is NR24 and Y2 is N; or
Y1 is N and Y2 is NR24;
R24 is H or C1-C3 alkyl;
ring A is phenyl or a 5- or 6-membered heteroaryl comprising 1-4 heteroatoms selected from N, O and S;
ring B is phenyl or a 5- or 6-membered heteroaryl comprising 1-4 heteroatoms selected from N, O and S,
Q is —O—, —NR20—, —CR22R23—, —CR22R23O—, or —CR22R23NH—; wherein R20 is H or alkyl, R22 is H, halogen, hydroxy, C1-C3 alkyl, or C1-C3 alkoxy, R23 is H, halogen, or C1-C3 alkyl, or R22 and R23 together with the carbon atom to which they are attached, form a carbonyl;
R2′ is C1-C6 alkyl;
each G is independently selected from halogen, OH, CN, alkyl optionally substituted with one or more R5, and alkoxy optionally substituted with one or more R5;
each R2 is independently H, halogen, —C(O)O-alkyl, or C1-C3alkyl optionally substituted with 1-3 halogens, provided that not more than one R2 is —C(O)O-alkyl;
R3 is H; halogen; alkenyl optionally substituted with cycloalkyl or heterocycloalkyl; heterocycloalkyl optionally substituted with —C(O)-alkyl; heterocycloalkenyl optionally substituted with C(O)-alkyl; heterocycloalkylalkyl optionally substituted with C(O)-alkyl; or heteroaryl optionally substituted with haloalkyl, cycloalkyl, or cycloalkylalkyl;
R4 is H; alkyl; cycloalkyl optionally substituted with haloalkyl or —C(O)-alkenyl; heterocycloalkyl optionally substituted with —C(O)-alkyl, —C(O)-alkenyl, or —C(O)-cycloalkyl; or heterocycloalkylalkyl optionally substituted with —C(O)-alkyl, —C(O)—CH2—OH, or heteroaryl;
R5 is halogen or OH;
v is 0, 1, 2, 3, or 4;
p is 0, 1, 2, 3, or 4; and
q is 0, 1, or 2.

### Claim 4 (depends on 1)

A compound of claim 1, having Formula (Ia) or (Ib):
or a pharmaceutically acceptable salt, a tautomer, a stereoisomer, or a deuterated analog thereof, wherein:
Y1 is NR24 and Y2 is N; or
Y1 is N and Y2 is NR24;
R24 is H or C1-C3 alkyl;
ring A is phenyl or a 5- or 6-membered heteroaryl comprising 1-4 heteroatoms selected from N, O and S;
ring B is phenyl or a 5- or 6-membered heteroaryl comprising 1-4 heteroatoms selected from N, O and S,
Q is —O—, —NR20—, —CR22R23—, —CR22R23O—, or —CR22R23NH—; wherein R20 is H or alkyl, R22 is H, halogen, hydroxy, C1-C3 alkyl, or C1-C3 alkoxy, R23 is H, halogen, or C1-C3 alkyl, or R22 and R23 together with the carbon atom to which they are attached, form a carbonyl;
R21 is C1-C6 alkyl;
each G is independently selected from halogen, OH, CN, alkyl optionally substituted with one or more R5, and alkoxy optionally substituted with one or more R5;
each R2 is independently H, halogen, —C(O)O-alkyl, or C1-C3alkyl optionally substituted with 1-3 halogens, provided that not more than one R2 is —C(O)O-alkyl;
R3 is H; halogen; alkenyl optionally substituted with cycloalkyl or heterocycloalkyl; heterocycloalkyl optionally substituted with —C(O)-alkyl; heterocycloalkenyl optionally substituted with C(O)-alkyl; heterocycloalkylalkyl optionally substituted with C(O)-alkyl; or heteroaryl optionally substituted with haloalkyl, cycloalkyl, or cycloalkylalkyl;
R4 is H; alkyl; cycloalkyl optionally substituted with haloalkyl or —C(O)-alkenyl; heterocycloalkyl optionally substituted with —C(O)-alkyl, —C(O)-alkenyl, or —C(O)-cycloalkyl; or heterocycloalkylalkyl optionally substituted with —C(O)-alkyl, —C(O)—CH2—OH, or heteroaryl;
R5 is halogen or OH;
v is 0, 1, 2, 3, or 4;
p is 0, 1, 2, 3, or 4; and
q is 0, 1, or 2.

### Claim 5 (depends on 3)

The compound of claim 3, wherein Q is —NH—, N(CH3)—, —O—, —CH2—, —C(O)—, —CH2—O—, —CF2—, —CHF—, —CH2—NH—, —CH(OH)—, —C(O)—NH—, or —CH(OCH3)—.

### Claim 6 (depends on 3)

The compound according to claim 3, wherein Q is —NH— or —O—.

### Claim 7 (depends on 3)

The compound according to claim 3, wherein:
v is 0, 1, 2, or 3;
each G is independently selected from halogen, CN, and C1-C3alkyl optionally substituted with 1-3 R5;
each R2 is H, halogen, or CH3; and
R5 is halogen or OH.

### Claim 8 (depends on 7)

The compound according to claim 7, wherein:
v is 0, 1, or 2;
each G is independently selected from Cl, F, CN, and C1-C3alkyl substituted with 1-3 R5;
each R2 is H, Cl, F, or CH3; and
R5 is halogen.

### Claim 9 (depends on 8)

The compound of claim 8, wherein R5 is Cl or F.

### Claim 10 (depends on 3)

The compound of claim 3, having one of the following formulae:
or a pharmaceutically acceptable salt, a tautomer, a stereoisomer, or a deuterated analog of any of formulae (IIa), (IIb), (IIc), (IId), (IIe), or (IIf); wherein:
each G is independently selected from Cl, F, CN, and C1-C3alkyl substituted with 1-3 R5; and
R5 is halogen.

### Claim 11 (depends on 10)

The compound according to claim 10, having one of the following formulae:
or a pharmaceutically acceptable salt, a tautomer, a stereoisomer, or a deuterated analog of any of formulae (IIIa), (IIIb), (IIIc), (IIId), (IIIe) or (IIIf); wherein:
G is Cl, F, or CN.

### Claim 12 (depends on 10)

The compound of claim 10, wherein R3 is H; halogen; C2-C4alkenyl optionally substituted with cyclopropyl or heterocycloalkyl; heterocycloalkyl optionally substituted with C(O)—CH3; heterocycloalkenyl optionally substituted with C(O)—CH3; heterocycloalkylalkyl optionally substituted with C(O)—CH3; or 5-6 membered heteroaryl optionally substituted with haloalkyl, cyclopropyl, or cyclopropyl-CH2—.

### Claim 13 (depends on 10)

The compound of claim 10, wherein R4 is H; C1-C3alkyl; cycloalkyl optionally substituted with haloalkyl or —C(O)-alkenyl; heterocycloalkyl optionally substituted with —C(O)—CH3, —C(O)—CH═CH2, or —C(O)-cyclopropyl; heterocycloalkylalkyl optionally substituted with —C(O)—CH3; —C(O)—CH2—OH; or 5-6 membered heteroaryl.

### Claim 14 (depends on 3)

The compound of claim 3, having one of the following formulae:
or a pharmaceutically acceptable salt, a tautomer, a stereoisomer, or a deuterated analog of any of formulae (IIa), (IIIb), (IIIc), (IIId), (IIIe) or (IIIf); wherein:
G is Cl, F, or CN;
R3 is H; halogen; C2-C4alkenyl optionally substituted with cyclopropyl or heterocycloalkyl; heterocycloalkyl optionally substituted with C(O)—CH3; heterocycloalkenyl optionally substituted with C(O)—CH3; heterocycloalkylalkyl optionally substituted with C(O)—CH3; or 5-6 membered heteroaryl optionally substituted with haloalkyl, cyclopropyl, or cyclopropyl-CH2—;
R4 is H; C1-C3alkyl; cycloalkyl optionally substituted with haloalkyl or —C(O)-alkenyl; heterocycloalkyl optionally substituted with —C(O)—CH3—C(O)—CH═CH2, or —C(O)-cyclopropyl; heterocycloalkylalkyl optionally substituted with —C(O)—CH3; —C(O)—CH2—OH; or 5-6 membered heteroaryl.

### Claim 15 (depends on 14)

The compound of claim 14, wherein:
R3 is H; and
R4 is H.

### Claim 16 (depends on 14)

The compound of claim 14, wherein:
R3 is H;
R4 is H; and
V is NR24 and Y2 is N.

### Claim 17 (depends on 14)

The compound of claim 14, wherein:
R3 is H;
R4 is H; and
Y1 is N and Y2 is NR24.

### Claim 18 (depends on 16)

The compound of claim 16, wherein:
R24 is H or methyl.

### Claim 19 (depends on 14)

The compound of claim 14, wherein: R21 is methyl or ethyl.

### Claim 20 (depends on 1)

A compound of claim 1, having one of the following formulae:
or a pharmaceutically acceptable salt, a tautomer, a stereoisomer, or a deuterated analog of any of formulae (IIIa), (IIIb), (IIIc), (IIId), (IIIe) or (IIIf); wherein:
Y1 is NR24 and Y2 is N; or
Y1 is N and Y2 is NR24
ring A is phenyl;
ring B is phenyl or 6-membered heteroaryl comprising 1-4 heteroatoms selected from N, O and S,
Q is —NH— or —O—;
R24 is H or C1-C3 alkyl;
R21 is C1-C6 alkyl optionally substituted with halogen, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, wherein the aryl, heteroaryl, cycloalkyl, heterocycloalkyl are optionally substituted with —O—C1-C6 alkyl; NH2, NH—C1-C6 alkyl, cycloalkyl; or C2-C6 alkenyl;
G is Cl, F, or CN;
R3 is H;
R4 is H.

### Claim 21 (depends on 1)

A compound of claim 1, having one of the following formulae:
or a pharmaceutically acceptable salt, a tautomer, a stereoisomer, or a deuterated analog of any of formulae (IIIa), (IIIb), (IIIc), (IIId), (IIIe) or (IIIf); wherein:
Y1 is NR24 and Y2 is N;
Y1 is N and Y2 is NR24;
ring A is phenyl;
ring B is 6-membered heteroaryl comprising 1-4 heteroatoms selected from N, O and S,
Q is —NH— or —O—;
R24 is H or C1-C3 alkyl;
R21 is C1-C3 alkyl;
G is Cl, F, or CN;
R3 is H;
R4 is H.

### Claim 22 (depends on 21)

The compound of claim 21, wherein Y1 is NR24 and Y2 is N.

### Claim 23 (depends on 21)

The compound of claim 21, wherein Y1 is N and Y2 is NR24.

### Claim 24 (depends on 21)

The compound of claim 21, wherein R24 is H or methyl.

### Claim 25 (depends on 24)

The compound of claim 24, wherein R21 is methyl or ethyl.

### Claim 26 (depends on 1)

A formic acid salt according to the compound of claim 1.

### Claim 27

A compound selected from Table 1, or a pharmaceutically acceptable salt thereof.

### Claim 28 (depends on 1)

A compound according to claim 1, wherein the compound is a non-covalent inhibitor of TEAD.

### Claim 29 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1, and a pharmaceutically acceptable carrier.

### Claim 30 (depends on 29)

The pharmaceutical composition of claim 29, further comprising a second pharmaceutical agent.

### Claim 31 (depends on 1)

A method for treating a subject with a disease or condition mediated by YAP/TEAD, said method comprising administering to the subject an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt, deuterated analog, a tautomer or a stereoisomer thereof, or a pharmaceutical composition thereof.

### Claim 32 (depends on 31)

The method of claim 31, wherein the disease or condition is a cancer, a neurodegenerative disease, a heart related disorder, or a kidney-related disorder.

### Claim 33 (depends on 31)

The method of claim 31, wherein the disease or condition is polycystic kidney disease, Alzheimer's disease, arrhythmogenic cardiomyopathy, Holt-Oram syndrome, liver cancer, epithelioid hemangioendothelioma, breast cancer, lung cancer, malignant mesothelioma, pancreatic cancer, kaposi sarcoma, uveal melanoma, renal cell carcinoma, colorectal cancer, multiple myeloma, neurofibromatosis Type 2, glioma, or glioblastoma.

### Claim 34 (depends on 31)

The method according to claim 31, further comprising administering one or more additional therapeutic agents.

### Claim 35 (depends on 34)

The method according to claim 34, wherein the one or more additional therapeutic agents is one or more of i) an alkylating agent; ii) an antibiotic; iii) an antimetabolite; iv) an immune checkpoint agent; v) a hormone or hormone antagonist; vi) a taxane; vii) a retinoid; viii) an alkaloid; ix) an antiangiogenic agent; x) a topoisomerase inhibitor; xi) a kinase inhibitor; xii) a targeted signal transduction inhibitor; xiii) a biological response modifier; xiv) an IDO inhibitor; xv) a chemotherapeutic agent; xvi) a BRAF inhibitor; xvii) a Mek inhibitor; xviii) c-Kit mutant inhibitor, xix) an EGFR inhibitor, xx) an epigenetic modulator; xxi) other adenosine axis blockade agents; and xxiii) an anti-ErbB2 mAb.
